| Literature DB >> 31484465 |
Maria Maddalena Di Fiore1, Raffaele Boni2, Alessandra Santillo3, Sara Falvo1, Alessandra Gallo4, Sabrina Esposito1, Gabriella Chieffi Baccari1.
Abstract
This article reviews the animal models and experimental designs that have been used during the past twenty years to demonstrate the prominent role played by d-aspartate (d-Asp) in the reproduction of vertebrates, from amphibians to humans. We have tabulated the findings of in vivo and in vitro experiments that demonstrate the effects of d-Asp uptake on hormone production and gametogenesis in vertebrate animal models. The contribution of each animal model to the existing knowledge on the role of d-Asp in reproductive processes has been discussed. A critical analysis of experimental designs has also been carried out. Experiments performed on wild animal species suggest a role of d-Asp in the mechanisms that regulate the reproductive cycle. Several in vivo and in vitro studies carried out on mouse and rat models have facilitated an understanding of the molecular pathways activated by D-Asp in both steroidogenesis and spermatogenesis, with particular emphasis on testosterone biosynthesis. Some attempts using d-Asp for the improvement of reproductive activity in animals of commercial interest have yielded mixed results. The increased transcriptome activity of enzymes and receptors involved in the reproductive activity in d-Asp-treated broiler roosters revealed further details on the mechanism of action of d-Asp on the reproductive processes. The close relationship between d-Asp and reproductive activity has emerged, particularly in relation to its effects exerted on semen quality, proposing therapeutic applications of this amino acid in andrology and in medically-assisted procreation techniques.Entities:
Keywords: ">d-aspartate; N-methyl-; hypothalamus-pituitary-gonad axis; sex steroid hormones; spermatogenesis; steroidogenesis; testosterone
Mesh:
Substances:
Year: 2019 PMID: 31484465 PMCID: PMC6770039 DOI: 10.3390/biom9090445
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Wild animals: in vivo experiments.
| BREEDING SEASON | OUT-OF-BREEDING SEASON | ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Injections of 2 µmol/g b.w./d D-Asp for 10–15 days |
|
|
|
|
| ||||
|
| |||||||||
|
| +96% | >1000% E2 | +100% | +67% T | Burrone et al. [ | ||||
|
| +450% | −60% T | +400% | +140% D-AspO activity | Burrone et al. [ | ||||
|
| |||||||||
| One Injection of |
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
| ||
|
| |||||||||
|
| +500% | +800% | +475% T | +25% T | Raucci et al. [ | ||||
|
| +255% T | +33% T | Raucci and Di Fiore [ | ||||||
| ♀ | |||||||||
|
| +900% | +775% | −52% T | −21% T | Di Fiore et al. [ | ||||
|
| −82% T | −47% T | −50% T | −83% T | Raucci and Di Fiore [ | ||||
|
| |||||||||
|
| +140% | +100% | +32% T | +20% T | +800% | +500% | +96% T | +78% T | Raucci et al. [ |
|
| +5% T | +23% T | +450% T | +1150% T | |||||
| ♀ | |||||||||
|
| >1000% | >1000% | −37% T | −12% T | Assisi et al. [ | ||||
|
| −42% T | −28% T | Raucci and Di Fiore [ | ||||||
Wild animals: in vitro experiments.
| Incubation | Increase/Decrease | References | |
|---|---|---|---|
|
| +2 μmol/mL D-Asp (3 h) | −62%T | Di Fiore et al. [ |
|
| +2 μmol/mL D-Asp (3 h) | −56%T | |
|
| +2 μmol/mL D-Asp (3 h) | +700% Aromatase activity | Assisi et al. [ |
|
| +2 μmol/mL D-Asp (3 h) | +566% Aromatase activity | |
|
| +1–2 mM D-Asp (3 h) | +33–150% T | Di Fiore et al. [ |
Laboratory animals: in vivo long-term experiments.
| D-Asp Uptake | Increase/Decrease | References | |
|---|---|---|---|
|
| +14–20% IVF | Raspa et al. [ | |
| 20 mM D-Asp drinking solution | |||
|
| |||
|
| +71% T | ||
|
| +25–46% T | ||
|
| |||
|
| + 75% mitochondrial ROS | Chandrashakar and Muralidhara [ | |
|
| |||
| +460–720% | +70% T | Topo et al. [ | |
| +580% | Topo et al. [ | ||
| +100% | +100–120% T | Topo et al. [ | |
| +100% | +40% P | Di Fiore et al. [ |
Laboratory animals: in vivo short-term experiments.
| D-Asp Uptake | Increase/Decrease | References | |||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| ||
|
|
| ||||||
|
| +133% | +311% | +150% NMDA | D’Aniello et al. [ | |||
|
| >1000% | >1000% | +125–166% NMDA | ||||
|
| +152% | +267% | +200–860% NMDA | ||||
|
| +500% | +110% | +70% | + 900% T | +600% T | + 450% T | Falvo et al. [ |
|
| >1000% | >1000% | +145% PRL | +36% T | +236% T | D’Aniello et al. [ | |
|
| +288% | +288% | +211% | +26% T | +80% P | +90% P | Di Fiore et al. [ |
Laboratory animals: in vitro experiments.
| Incubation | Increase/Decrease | References | |
|---|---|---|---|
|
| |||
|
| +1–10 mM D-Asp (4 wks) | −21–71% Acr-GFP | Tomita et al [ |
|
| +200 µM D-Asp (0.5-2 h) | +60–100% GluA1 | Santillo et al. [ |
| +50 µM NMDA (0.5–4 h) | +66–116% GluA1 | Santillo et al. [ | |
|
| +0.1 nM D-Asp+10 ng/mL hCG (48 h) | +25% T | Di Nisio et al. [ |
|
| |||
|
| +0–1 mM D-Asp (2 h) | +50–280% MDA (cytosol) | Chandrashakar and Muralidhara [ |
|
| +0.2 mM D-Asp (2–24 h) | +112% StAR mRNA | Raucci et al. [ |
|
| +200 µM D-Asp (16 h) | +50% T | Nagata et al. [ |
| +0.1 or 1.0 mM D-Asp (1h) | +142–200% T | Topo et al. [ | |
|
| +1 mM D-Asp (0.5 h) | +105% oxytocin | Pampillo et al. [ |
|
| +0.1–1 mM D-Asp (1 h) | +150–300% PRL | D’Aniello et al. [ |
| +0.1 mM NMDA (1 h) | +185% GH | ||
| +0.1–1 mM D-Asp (4 h) | +11–13% PRL | Pampillo et al. [ | |
| +0.1–1 mM D-Asp (4 h) | +15–25 % PRL | ||
| + 0.01–0.1 mM NMDA (4 h) | +71–110 % PRL | ||
|
| +0.1 mM D-Asp (0.5 h) | −35% oxytocin | Pampillo et al. [ |
|
| +1 mM D-Asp (0.5–4 h) | +450% PRL | D’Aniello et al. [ |
| +0.1 mM NMDA (1 h) | +202% LH | ||
Livestock animals: in vivo experiments.
|
|
|
|
|
|
| |||
| Oral administration of 100–200 mg | |||
|
| +120–680% StAR mRNA | Ansari et al. [ | |
|
| +10–24% T | ||
|
| +sperm motility | Ansari et al. [ | |
|
| |||
| S.C. administration of 22.2 mg D-Asp/kg b.w. every 3 or 6 days for 1 month | |||
|
| +40% LH | Boni et al. [ | |
|
|
|
|
|
|
| |||
| S.C. injection of 44.4 mg D-Asp/kg b.w. | |||
|
| +650% (24 h) | Boni et al. [ | |
|
| >1000% (12–24 h) | +200% NMDA (12 h) | |
|
| +125% (12–24 h) | +250% NMDA (12 h) | |
|
| >1000% (3 h) | >1000% NMDA (5–12 h) |
Humans: in vivo long-term experiments.
| Increase/Decrease | References | |
|---|---|---|
| Oral administration of: | ||
| DADAVit® for 12 days | +33% LH | Topo et al. [ |
| 6 g D-Asp for 14 days | −15% T in resistance trained men | Melville et al. [ |
| 6 g D-Asp for 3 months | −95% E2 in resistance trained men | Melville et al. [ |
| DADAVit® or GENADIS® | +sperm concentration and motility in asthenozoospermic and oligoasthenozoospermic men | D’Aniello et al. [ |
Figure 1The scheme summarizes the effects of D-Asp administrations on the hypothalamic–pituitary–gonad axis in different classes of vertebrates. The effects of the amino acid on the male and female reproductive process are shown in the boxes.